BCM
MIST icon

Bronte Capital Management’s Milestone Pharmaceuticals MIST Stock Holding History

Bronte Capital Management’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.3K Buy
14,390
+3,976
+38% +$6.36K ﹤0.01% 56
2026
Q1 		$12.4K Hold
10,414
– – ﹤0.01% 52
2025
Q4 		$21K Buy
+10,414
New +$22.4K ﹤0.01% 42

Other funds holding MIST

PCM
Pavaki Capital Management Pueblo, Colorado $287M AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Bronte Capital Management's MIST Position: Q2 2026 in Review

Bronte Capital Management increased its Milestone Pharmaceuticals (MIST) stake by 38% in Q2 2026, buying an estimated $6.36K and bringing the position to 14,390 shares worth $19.3K. The position accounts for ﹤0.01% of the portfolio, ranked #56.

Bronte Capital Management first reported a position in MIST in Q4 2025 and has held it in 3 quarters since. The position peaked at $21K in Q4 2025. 78 funds tracked by Wall St. Rank hold MIST as of Q2 2026.

  • Bronte Capital Management held 14,390 shares of Milestone Pharmaceuticals worth $19.3K as of Q2 2026.
  • Bronte Capital Management bought 3,976 Milestone Pharmaceuticals shares in Q2 2026, an estimated $6.36K.
  • Milestone Pharmaceuticals made up ﹤0.01% of Bronte Capital Management's portfolio in Q2 2026, its #56 holding.
  • Bronte Capital Management first reported a position in Milestone Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Bronte Capital Management's Milestone Pharmaceuticals position peaked at $21K in Q4 2025.
  • 78 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q2 2026.

Based on Bronte Capital Management's 13F filing for Q2 2026, filed 5 Aug 2026.